Evidence map›Paper›PMID 41572058›Full record

ReviewPharmacological reports : PR2026

Metformin in skin diseases: the role of gut microbiota and immune response.

Aneta Kiecka, Barbara Macura, Marian Szczepanik

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aneta KieckaChair of Biomedical Sciences, Faculty of Health Sciences, Institute of Physiotherapy, Jagiellonian University Medical College, Kopernika 7a, Kraków, 31-034, Poland. aneta.kiecka@uj.edu.pl.
Barbara MacuraChair of Biomedical Sciences, Faculty of Health Sciences, Institute of Physiotherapy, Jagiellonian University Medical College, Kopernika 7a, Kraków, 31-034, Poland.
Marian SzczepanikChair of Biomedical Sciences, Faculty of Health Sciences, Institute of Physiotherapy, Jagiellonian University Medical College, Kopernika 7a, Kraków, 31-034, Poland.

Funding

This publication was supported by internal research funding from the Jagiellonian University Medical College N43/GBS/000006
6 · The paper itself

Abstract

Metformin is one of the most commonly prescribed drugs for the treatment of type 2 diabetes (T2D). Its mechanism of action involves lowering blood glucose levels by enhancing peripheral tissue sensitivity to insulin, inhibiting hepatic glucose production, and decreasing intestinal glucose absorption. Recent research has shown that metformin may also have therapeutic potential beyond diabetes, including the treatment of chronic pain, cancer, and polycystic ovary syndrome. Additionally, metformin is used in managing various skin diseases such as atopic dermatitis (AD), allergic contact dermatitis (ACD), and psoriasis. It has also been found to influence skin aging processes and promote wound healing. These effects may be attributed to metformin’s immunomodulatory properties and its ability to modulate the gut microbiota. The aim of this review is to summarize the current evidence on the effects of metformin on gut microbial composition and the immune system, as well as its potential role in the treatment of skin diseases.

Indexed as

Gastrointestinal MicrobiomeMetforminSkin DiseasesAnimalsDiabetes Mellitus, Type 2HumansHypoglycemic AgentsWound HealingHypoglycemic AgentsMetforminAtopic dermatitisImmunomodulationMetforminSkin diseaseWound healing

Identifiers

PMID41572058

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.